IN2015DN00334A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00334A
IN2015DN00334A IN334DEN2015A IN2015DN00334A IN 2015DN00334 A IN2015DN00334 A IN 2015DN00334A IN 334DEN2015 A IN334DEN2015 A IN 334DEN2015A IN 2015DN00334 A IN2015DN00334 A IN 2015DN00334A
Authority
IN
India
Prior art keywords
disorders
diseases
compounds
formula
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Amy Allan
Bryan Branstetter
Brian Dyck
Michael I Weinhouse
Laurent Gomez
Tami Jo Marrone
Marco Peters
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of IN2015DN00334A publication Critical patent/IN2015DN00334A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IN334DEN2015 2012-06-18 2013-06-18 IN2015DN00334A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661091P 2012-06-18 2012-06-18
PCT/US2013/046415 WO2013192229A1 (en) 2012-06-18 2013-06-18 Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds

Publications (1)

Publication Number Publication Date
IN2015DN00334A true IN2015DN00334A (enrdf_load_stackoverflow) 2015-06-12

Family

ID=49756458

Family Applications (2)

Application Number Title Priority Date Filing Date
IN334DEN2015 IN2015DN00334A (enrdf_load_stackoverflow) 2012-06-18 2013-06-18
IN335DEN2015 IN2015DN00335A (enrdf_load_stackoverflow) 2012-06-18 2013-06-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN335DEN2015 IN2015DN00335A (enrdf_load_stackoverflow) 2012-06-18 2013-06-18

Country Status (17)

Country Link
US (7) US9284335B2 (enrdf_load_stackoverflow)
EP (3) EP2861605B1 (enrdf_load_stackoverflow)
JP (2) JP6129960B2 (enrdf_load_stackoverflow)
KR (2) KR102191816B1 (enrdf_load_stackoverflow)
CN (2) CN104583217B (enrdf_load_stackoverflow)
AU (3) AU2013277294C1 (enrdf_load_stackoverflow)
BR (2) BR112014031731B1 (enrdf_load_stackoverflow)
CA (2) CA2877146C (enrdf_load_stackoverflow)
DK (2) DK3489238T3 (enrdf_load_stackoverflow)
ES (2) ES2904267T3 (enrdf_load_stackoverflow)
IL (2) IL236232A (enrdf_load_stackoverflow)
IN (2) IN2015DN00334A (enrdf_load_stackoverflow)
MX (2) MX359615B (enrdf_load_stackoverflow)
NZ (2) NZ703949A (enrdf_load_stackoverflow)
RU (2) RU2653054C2 (enrdf_load_stackoverflow)
SG (3) SG10201703253XA (enrdf_load_stackoverflow)
WO (2) WO2013192225A1 (enrdf_load_stackoverflow)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2373540T3 (es) * 2000-08-10 2012-02-06 Cold Spring Harbor Laboratory Entrenamiento cognitivo aumentado.
SG10201703253XA (en) * 2012-06-18 2017-06-29 Dart Neuroscience (Cayman) Ltd Substituted pyridine azolopyrimidine-5-(6h)-one compounds
JP6396229B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396230B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396231B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
GB201406486D0 (en) * 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017046603A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds and new uses thereof
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JOP20170164A1 (ar) * 2016-08-25 2019-01-30 Lilly Co Eli مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
WO2018073251A1 (en) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
US10912773B2 (en) 2016-10-28 2021-02-09 H. Lundbeck A/S Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors
US10905688B2 (en) 2016-10-28 2021-02-02 H. Lundbeck A/S Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors
CN110337437B (zh) 2016-12-28 2023-02-03 达特神经科学有限公司 作为pde2抑制剂的取代的吡唑并嘧啶酮化合物
SG10201910821XA (en) * 2016-12-30 2020-01-30 Frequency Therapeutics Inc 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
JP7053645B2 (ja) * 2017-02-23 2022-04-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 化合物ｉｉｉの新しい医学的使用
AR112457A1 (es) 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
TW201920188A (zh) * 2017-08-10 2019-06-01 美商美國禮來大藥廠 [1,2,4]三唑衍生物
US11434247B1 (en) 2017-11-27 2022-09-06 Dart Neuroscience Llc Substituted furanopyrimidine compounds as PDE1 inhibitors
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
EP3908285A4 (en) 2019-01-07 2022-10-19 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
US20220280517A1 (en) * 2019-08-22 2022-09-08 Intra-Cellular Therapies, Inc. Organic compounds
GB201914860D0 (en) * 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
EP4389746A3 (en) * 2022-12-21 2024-07-03 Recordati Industria Chimica E Farmaceutica SPA P2x3 receptor antagonists
WO2025024543A1 (en) * 2023-07-24 2025-01-30 Bpgbio, Inc. Tricyclic ube2k modulators and methods for their use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046366A1 (de) 1980-12-09 1982-07-08 Bayer Ag, 5090 Leverkusen Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung
DE3146599A1 (de) 1981-11-25 1983-07-07 Basf Ag, 6700 Ludwigshafen Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP0181282A1 (de) 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
JPS62135475A (ja) * 1985-09-30 1987-06-18 チバ−ガイギ−　アクチエンゲゼルシヤフト ２−置換−ｅ−融合−〔１，２，４〕トリアゾロ−〔１，５−Ｃ〕ピリミジン
EP0217748B1 (en) 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2659329B1 (fr) * 1990-03-09 1994-06-03 Adir Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant.
AU2483599A (en) * 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
DE10012373A1 (de) * 2000-03-14 2001-09-20 Dresden Arzneimittel Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
ES2373540T3 (es) 2000-08-10 2012-02-06 Cold Spring Harbor Laboratory Entrenamiento cognitivo aumentado.
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
EP2023729B1 (en) * 2006-06-06 2016-05-04 Intra-Cellular Therapies, Inc. Organic compounds
EP2139333A4 (en) * 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRID- [3,2-E] - [1,2,4] -TRIAZOL- [4,3-C] -PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
CN102014928A (zh) 2007-05-15 2011-04-13 海利空医疗公司 使用小干扰RNA(siRNA)鉴别参与记忆形成的基因的方法
US20100203624A1 (en) 2007-09-26 2010-08-12 Ge Healthcare Bioscience Bioprocess Corp. Three dimensional disposable bioreactor
EP2939676A1 (en) 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010065149A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322905A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
JP2012518685A (ja) 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US9434730B2 (en) * 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
SG10201703253XA (en) * 2012-06-18 2017-06-29 Dart Neuroscience (Cayman) Ltd Substituted pyridine azolopyrimidine-5-(6h)-one compounds

Also Published As

Publication number Publication date
AU2013277298A1 (en) 2015-02-05
MX2014015737A (es) 2015-09-16
US10092575B2 (en) 2018-10-09
JP2015526395A (ja) 2015-09-10
AU2013277294A1 (en) 2015-02-05
US9533996B2 (en) 2017-01-03
US20170182052A1 (en) 2017-06-29
EP2861603A4 (en) 2015-11-11
IN2015DN00335A (enrdf_load_stackoverflow) 2015-06-12
HK1208023A1 (en) 2016-02-19
EP2861605A4 (en) 2016-01-13
AU2013277298B2 (en) 2017-09-07
MX359615B (es) 2018-10-03
HK1208024A1 (en) 2016-02-19
KR102087756B1 (ko) 2020-03-12
BR112014031730B1 (pt) 2023-05-16
EP3489238B1 (en) 2021-10-13
US9284335B2 (en) 2016-03-15
JP2015526394A (ja) 2015-09-10
IL236232A0 (en) 2015-02-01
NZ703950A (en) 2016-10-28
US20170209459A1 (en) 2017-07-27
US20150158885A1 (en) 2015-06-11
NZ703949A (en) 2016-10-28
BR112014031730A2 (pt) 2017-06-27
DK3489238T3 (da) 2022-01-10
AU2017272245A1 (en) 2018-01-04
SG10201703253XA (en) 2017-06-29
WO2013192229A1 (en) 2013-12-27
DK2861603T3 (en) 2019-03-04
KR20150063030A (ko) 2015-06-08
WO2013192229A8 (en) 2015-09-03
CN104583213A (zh) 2015-04-29
RU2659779C2 (ru) 2018-07-04
JP6129960B2 (ja) 2017-05-17
CA2877149A1 (en) 2013-12-27
US10376514B2 (en) 2019-08-13
BR112014031731B1 (pt) 2022-12-06
EP2861603B1 (en) 2018-12-19
RU2653054C2 (ru) 2018-05-07
US20190046535A1 (en) 2019-02-14
SG11201408395WA (en) 2015-01-29
US20160075719A1 (en) 2016-03-17
CA2877149C (en) 2021-01-19
EP3489238A1 (en) 2019-05-29
AU2013277294C1 (en) 2018-02-08
KR102191816B1 (ko) 2020-12-17
ES2904267T3 (es) 2022-04-04
BR112014031731A2 (pt) 2017-06-27
JP6240180B2 (ja) 2017-11-29
RU2015100209A (ru) 2016-08-10
CA2877146A1 (en) 2013-12-27
CN104583213B (zh) 2018-10-26
IL236232A (en) 2016-10-31
US9175010B2 (en) 2015-11-03
US10105367B2 (en) 2018-10-23
EP2861605A1 (en) 2015-04-22
EP3489238B8 (en) 2022-02-16
ES2715325T3 (es) 2019-06-03
MX357320B (es) 2018-07-04
EP2861605B1 (en) 2017-05-03
EP2861603A1 (en) 2015-04-22
MX2014015740A (es) 2015-11-06
IL236233A0 (en) 2015-02-01
CN104583217B (zh) 2017-11-17
AU2017272245B2 (en) 2019-08-29
US9499562B2 (en) 2016-11-22
CN104583217A (zh) 2015-04-29
KR20150063028A (ko) 2015-06-08
AU2013277294B2 (en) 2017-04-13
US20130338139A1 (en) 2013-12-19
US20160031901A1 (en) 2016-02-04
RU2015100213A (ru) 2016-08-10
CA2877146C (en) 2020-10-20
WO2013192225A1 (en) 2013-12-27
IL236233A (en) 2016-10-31
SG11201408397SA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
IN2015DN00334A (enrdf_load_stackoverflow)
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
MX2013005549A (es) Aminas heterociclicas y sus usos.
PH12015500525A1 (en) Formulations of enzalutamide
EP2925775A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLISM DISEASES AND DRESSINGS
EA201290909A1 (ru) Химические соединения
LT2925757T (lt) Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
IN2015DN00372A (enrdf_load_stackoverflow)
MX353299B (es) Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
MX2015003701A (es) Composiciones para tratamiento.
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
IL234606B (en) Innovative methods and compounds for the treatment of diseases
CR20140528A (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de Bace1
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
AP2014007905A0 (en) Novel compounds for the treatment of dyslipidemia and related diseases
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
MX2015008454A (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
SG11201504779YA (en) Methods and compositions relating to treatment of cancer